Literature DB >> 18618219

Fulminant type 1 diabetes mellitus observed in insulin receptor substrate 2 deficient mice.

T Arai1, H Hashimoto, K Kawai, A Mori, Y Ohnishi, K Hioki, M Ito, M Saito, Y Ueyama, M Ohsugi, R Suzuki, N Kubota, T Yamauchi, K Tobe, T Kadowaki, K Kosaka.   

Abstract

The objective of this study was to characterise the fulminant type 1 diabetes mellitus (DM) accompanying abrupt hyperglycaemia and ketonuria observed in insulin receptor substrate 2 (IRS2)-deficient mice. IRS2-deficient mice backcrossed onto the original C57BL/6J:Jc1 background (B6J-IRS2(-/-) mice) for more than 10 generations were used. Eight male IRS2-deficient mice with ketonuria and abrupt increase in plasma glucose concentrations over 25 mmol/l were used as the fulminant type 1 diabetic mice (diabetic mice) and 8 male IRS2-deficient mice (8 weeks old) without glycosuria were used as the control mice. Plasma metabolite, immunoreactive insulin (IRI) and C-peptide concentrations, hepatic energy metabolism related enzyme activities and histopathological change in pancreatic islets were investigated. The diabetic mice showed significantly higher plasma glucose and cholesterol concentrations and lower plasma IRI and C-peptide concentrations than the control mice. In livers of the diabetic mice, glycolytic and malate-aspartate shuttle enzyme activities decreased significantly and gluconeogenic, lipogenic and ketone body synthesis enzyme activities increased significantly compared to those in the control mice. The pancreatic islets of the diabetic mice decreased significantly in size and number of beta cells. The diabetic IRS2-deficient mice did not show the islet-related antibodies observed in the diabetic NOD mice in their sera. The characteristics of the diabetic IRS2-deficient mice resembled those of the human nonautoimmune fulminant type 1 DM. IRS2-deficient mice may be a useful animal model for studying the degradation mechanism of pancreatic beta cells in the process of development of fulminant type 1 DM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618219     DOI: 10.1007/s10238-008-0163-1

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  32 in total

1.  A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group.

Authors:  A Imagawa; T Hanafusa; J Miyagawa; Y Matsuzawa
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

2.  Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene.

Authors:  E Araki; M A Lipes; M E Patti; J C Brüning; B Haag; R S Johnson; C R Kahn
Journal:  Nature       Date:  1994-11-10       Impact factor: 49.962

3.  Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2.

Authors:  Y Kido; D J Burks; D Withers; J C Bruning; C R Kahn; M F White; D Accili
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

4.  Lactate dehydrogenase of lobster (Homarus americanus) tail muscle. I. Physical and chemical properties.

Authors:  H D Kaloustian; F E Stolzenbach; J Everse; N O Kaplan
Journal:  J Biol Chem       Date:  1969-06-10       Impact factor: 5.157

5.  Ontogenetic characteristics of enzyme activities and plasma metabolites in C57BL/6J:Jcl mice deficient in insulin receptor substrate 2.

Authors:  Haruo Hashimoto; Toshiro Arai; Akira Takeguchi; Kyouji Hioki; Yasuyuki Ohnishi; Kenji Kawai; Mamoru Ito; Ryo Suzuki; Toshimasa Yamauchi; Mitsuru Ohsugi; Muneo Saito; Yoshito Ueyama; Kazuyuki Tobe; Takashi Kadowaki; Norikazu Tamaoki; Kinori Kosaka
Journal:  Comp Med       Date:  2006-06       Impact factor: 0.982

6.  Malate dehydrogenase activities are lower in some types of peripheral leucocytes of dogs and cats with type 1 diabetes mellitus.

Authors:  E Magori; M Nakamura; A Inoue; A Tanaka; N Sasaki; H Fukuda; H Mizutani; T Sako; N Kimura; T Arai
Journal:  Res Vet Sci       Date:  2005-02       Impact factor: 2.534

7.  Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver.

Authors:  K Tobe; R Suzuki; M Aoyama; T Yamauchi; J Kamon; N Kubota; Y Terauchi; J Matsui; Y Akanuma; S Kimura; J Tanaka; M Abe; J Ohsumi; R Nagai; T Kadowaki
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

8.  Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia.

Authors:  N Kubota; K Tobe; Y Terauchi; K Eto; T Yamauchi; R Suzuki; Y Tsubamoto; K Komeda; R Nakano; H Miki; S Satoh; H Sekihara; S Sciacchitano; M Lesniak; S Aizawa; R Nagai; S Kimura; Y Akanuma; S I Taylor; T Kadowaki
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

Review 9.  A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidence.

Authors:  A Imagawa; T Hanafusa; J Miyagawa; Y Matsuzawa
Journal:  Ann Med       Date:  2000-11       Impact factor: 4.709

10.  Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages.

Authors:  P Newsholme; S Gordon; E A Newsholme
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

View more
  1 in total

1.  From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity.

Authors:  Darja Kanduc; Yehuda Shoenfeld
Journal:  Glob Med Genet       Date:  2020-08-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.